Pages that link to "Q36796914"

The following pages link to Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study (Q36796914):

Displaying 28 items.

• Risperidone versus other atypical antipsychotics for schizophrenia (Q24234950) (← links)
• Clozapine versus other atypical antipsychotics for schizophrenia (Q24236422) (← links)
• Risperidone versus typical antipsychotic medication for schizophrenia (Q24248755) (← links)
• Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. (Q30501297) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (Q33223628) (← links)
• The use of atypical antipsychotics in the management of schizophrenia. (Q33540449) (← links)
• Risperidone. A pharmacoeconomic review of its use in schizophrenia (Q33582654) (← links)
• Conventional versus novel antipsychotics: changing concepts and clinical implications (Q33787546) (← links)
• Tolerability of atypical antipsychotics (Q33876248) (← links)
• Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. (Q33922302) (← links)
• Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study (Q34201647) (← links)
• Effects of newer antipsychotics on extrapyramidal function (Q34481227) (← links)
• Adverse effects of atypical antipsychotics : differential risk and clinical implications (Q34583643) (← links)
• Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials (Q34707909) (← links)
• Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences (Q35073807) (← links)
• State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics (Q35073834) (← links)
• The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review (Q36262544) (← links)
• Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function (Q37338702) (← links)
• Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone (Q43610446) (← links)
• Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents (Q44019369) (← links)
• Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats (Q44169297) (← links)
• Atypical antipsychotics in therapy refractory schizophrenia (Q44784589) (← links)
• Resistance to excessive bodyweight gain in risperidone-injected rats (Q46422509) (← links)
• Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms (Q46788912) (← links)
• Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. (Q53903012) (← links)
• Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine (Q73959654) (← links)
• Correlation between neuroleptic binding to sigma(1) and sigma(2) receptors and acute dystonic reactions (Q74107161) (← links)
• The new antipsychotics, and their potential for early intervention in schizophrenia (Q74191791) (← links)